CAS 1269440-17-6

LGX818

Description:

LGX818, also known by its chemical name, is a small molecule that functions primarily as a selective inhibitor of certain kinases, particularly those involved in cancer cell proliferation and survival. It is designed to target specific mutations in the BRAF gene, which are commonly associated with various types of cancer, including melanoma. The compound exhibits high potency and selectivity, making it a promising candidate for targeted cancer therapies. LGX818 is typically characterized by its molecular structure, which includes specific functional groups that contribute to its biological activity. In terms of solubility, it is often formulated for optimal absorption and bioavailability in clinical settings. The pharmacokinetics of LGX818 involve its metabolism and excretion pathways, which are crucial for determining dosing regimens in therapeutic applications. As with many investigational drugs, ongoing research is focused on understanding its efficacy, safety profile, and potential side effects in patients. Overall, LGX818 represents a significant advancement in the field of targeted cancer treatment.

Formula: C₂₂H₂₇ClFN₇O₄S

InChI: InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1

InChI key: InChIKey=CMJCXYNUCSMDBY-ZDUSSCGKSA-N

SMILES: FC1=C(C=2C(=CN(C(C)C)N2)C3=NC(NC[C@@H](NC(OC)=O)C)=NC=C3)C=C(Cl)C=C1NS(C)(=O)=O

Synonyms:

• (S)-Methyl [1-[[4-[3-[5-chloro-2-fluoro-3-(methylsulfonamido)phenyl]-1-isopropyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
• Braftovi
• Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester
• Encorafenib
• Lgx 818
• Nvp-Lgx 818Nxa
• CS-1037
• Methyl N-[(2s)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
• LGX 818; LGX-818;LGX818
• LGX818, >=98%
• LGX818, Encorafenib
• ENCORAFENIB;LGX818; LGX-818
• methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate
• LGX 818 (S)-Methyl [1-[[4-[3-[5-chloro-2-fluoro-3-(methylsulfonamido)phenyl]-1-isopropyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
• Encorafenib (LGX818) USP/EP/BP
• LGX818
• methyl (S)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
• LGX818; LGX-818; LGX 818; ENCORAFENIB.

Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester

CAS: 1269440-17-6

Formula: C₂₂H₂₇ClFN₇O₄S

Purity: 98%

Color and Shape: Solid

Molecular weight: 540.0107

Ref: IN-DA000WF7

Encorafenib

CAS: 1269440-17-6

Encorafenib

Purity: ≥98%

Molecular weight: 540.01g/mol

Ref: 54-BUP00830

Encorafenib

CAS: 1269440-17-6

Encorafenib (LGX818) is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.

Formula: C₂₂H₂₇ClFN₇O₄S

Purity: 99.51% - 99.83%

Color and Shape: Solid

Molecular weight: 540.01

Ref: TM-T6487

Encorafenib

CAS: 1269440-17-6

Formula: C₂₂H₂₇ClFN₇O₄S

Molecular weight: 540.01

Ref: 4Z-E-183001

LGX 818

CAS: 1269440-17-6

Inhibitor of B-Raf mutant (V600E); anti-neoplastic

Formula: C₂₂H₂₇ClFN₇O₄S

Purity: Min. 95%

Color and Shape: White/Off-White Solid

Molecular weight: 540.01 g/mol

Ref: 3D-FC65061